MED19: A Potential Drug Target and Biomarker for RNA Polymerase II Transcription

Target Name: MED19

NCBI ID: G219541

MED19

MED19: A Potential Drug Target and Biomarker for RNA Polymerase II Transcription

RNA polymerase II (RNA-II) is a key transcription factor that plays a central role in gene expression and cell development. It is composed of multiple subunits, including subunit 19 (SU-19), which is a critical component of the complex that transports the RNA template to the loading site for RNA synthesis. The function of SU-19 is crucial for the regulation of gene expression, and alterations in its activity have been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting MED19, the subunit 19 homolog, has emerged as a promising strategy for the development of new drugs and biomarkers.

MED19 is a 25kDa protein that is highly conserved across various species, including humans. It is composed of a unique N-terminal domain, a transmembrane region, and a C-terminal domain that contains a conserved motor domain, a nucleotide-binding domain, and a C-terminal hypervariable region (HVR) that is involved in interactions with other subunits and the substrate RNA. The C-terminal domain of MED19 contains a unique farnesylated cysteine residue, which is critical for its stability and functions as a nucleotide-binding protein.

SU-19 is a 13kDa protein that is highly conserved across various species and is responsible for the delivery of the RNA template to the loading site for RNA synthesis. It is composed of a unique N-terminal domain, a transmembrane region, and a C-terminal domain that contains a nucleotide-binding domain and a C-terminal HVR. The N-terminal domain of SU-19 contains a unique farnesylated cysteine residue, which is critical for its stability and functions as a nucleotide-binding protein.

MED19 and SU-19 have been extensively studied, and their functions have been implicated in numerous biological processes, including cell growth, apoptosis, and transcriptional regulation. Several studies have shown that alterations in the activity of MED19 can have profound effects on gene expression and cell behavior. For example, studies have shown that MED19-/- mice have reduced DNA repair capacity, increased cell proliferation, and altered skeletal muscle mass, suggesting that its activity may be involved in the regulation of DNA repair and muscle growth.

In addition, MED19 has also been implicated in the regulation of cell apoptosis. Studies have shown that MED19 can induce cell apoptosis in various cell types, including cancer cells, and that its activity may be involved in the regulation of apoptosis-related genes, such as Bcl-2 and p53. This suggests that its activity may be involved in the regulation of cell life-and-death decisions.

Furthermore, several studies have suggested that MED19 may be involved in the regulation of gene expression and cell behavior by modulating the levels of various RNA species, including microRNA (miRNA), long non-coding RNA (lncRNA), and short non-coding RNA (snRNA). This suggests that its activity may be involved in the regulation of post-transcriptional gene expression and the control of cellular processes, such as cell signaling and protein synthesis.

Given the significant involvement of MED19 in various cellular processes, targeting it as a drug target or biomarker has significant potential. Strategies to inhibit MED19 activity have been proposed, including the use of small molecules, antibodies, and RNA-based therapies. For example, a small molecule inhibitor, N-[3-(2-methylpropyl)ammonio]-4-fluorobutane, has been shown to inhibit the activity of MED19, and this compound has been shown to be effective in animal models of cancer. Similarly, an antibody against MED19 has been shown to be effective in blocking its activity in cell culture and animal models of disease.

In conclusion, MED19 is a protein that is involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation. Its activity has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting MED19, the subunit 19 homolog, has emerged as a promising strategy for the development of new drugs and biomarkers. Further studies are needed to fully understand the functions of MED19 and its potential as a drug target or biomarker.

Protein Name: Mediator Complex Subunit 19

Functions: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors

The "MED19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MED19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets